Role of Advanced Microorganisms in Drug Development and Novel Drug Delivery Systems: Gut Microbiota, and other microorganisms in Multifunctional Nanocarriers drug delivery and Future Perspectives in Asian Healthcare

Abstract

Background: In the recent years advances in microbiology, microbial genomics, synthetic biology, microbiome research, and nanotechnology have reshaped pharmaceutical studies and how drug delivery systems are designed. In the past microorganisms were mostly seen as the agents that cause illness, but now they’re understood as useful biological materials for drug discovery and therapeutic innovation. Many microorganisms, like Streptomyces spp., Lactobacillus spp., Bifidobacterium spp., Saccharomyces cerevisiae, Escherichia coli, and bacteriophages, have played a big part in creating antibiotics, anticancer agents, probiotics, vaccines, and newer drug delivery platforms. Also, gut microbiota has become a key factor for drug metabolism, therapeutic success, immune modulation , and the broader idea of personalized medicine.

Methods: This was a qualitative cross-sectional study carried out from January to June 2025. Participants included healthcare professionals, pharmaceutical scientists, clinicians, academicians, and postgraduate researchers who were working in hospitals, clinics, universities, or within pharmaceutical companies across Pakistan, Saudi Arabia, and the United Arab Emirates (UAE). We used convenience sampling to bring people into the study, and the data came from 300 respondents. Information was gathered via semi-structured questionnaires, plus online interviews. Afterward, thematic analysis was used to examine what was collected, so major perceptions could be mapped out about how advanced microorganisms support drug development , gut microbiota investigations, and nanotechnology driven drug delivery systems.

Results: Out of the 300 participants, 40.0% came from Pakistan, 31.7% from Saudi Arabia, and the remaining 28.3% from the UAE, all participants are above > 18. What stood out was fairly solid awareness about the pharmaceutical relevance of microorganisms. Around 92.0% of respondents saw microorganisms as major sources for novel therapeutic compounds, and 94.0% also agreed on the importance of gut microbiota for drug metabolism as well as personalized medicine. People seemed especially convinced about specific groups: Streptomyces species were described as strong antibiotic producers, Saccharomyces cerevisiae as a helpful framework for recombinant therapeutics and Lactobacillus along with Bifidobacterium as probiotic microorganisms with real therapeutic promise. In addition, 95.7% of the respondents felt that multifunctional nanocarriers, and microbial derived delivery systems were promising routes for targeted drug delivery, better bioavailability, and lower systemic toxicity. Microbial derived therapeutics, gut microbiota centered interventions, engineered microorganisms, and multifunctional nanocarriers look like they’re paving the way for precision medicine and more targeted drug delivery. The plan is that combining microbiology, synthetic biology, artificial intelligence, and nanotechnology will speed up safer, and more effective therapeutic approaches in the future.